Transdermal Buprenorphine Induced Respiratory Acidosis in a Post TKR patient A Rare Case

Vishnu S, Sukesh Rao

Authors

Vishnu S, Sukesh Rao

Keywords:

respiratory acidosis, buprenorphine, transdermal patch, respiratory depression

Abstract

Post-operative pain management consists of a cocktail of drugs ranging from Nsaids, Opioids and Non-opioids. Transdermal Buprenorphine patch is commonly used in pain management of post-operative cases, musculoskeletal pain, cancerous and non-tumorous conditions. Buprenorphine is safely used because of its partial intrinsic activity and slow dissociation on Mu (µ) receptor causing prolonged analgesic effect with a ceiling for respiratory depression. Buprenorphine is commonly used in elderly patients and in patients with chronic renal failure. We report a probable case of buprenorphine patch induced respiratory depression and sedation leading to respiratory acidosis. Respiratory acidosis was managed symptomatically with oxygen therapy and removal of transdermal buprenorphine patch lead to the reversal of clinical condition. Awareness of this possible side effect of buprenorphine patch and unwarranted use should be avoided.

Downloads

How to Cite

Transdermal Buprenorphine Induced Respiratory Acidosis in a Post TKR patient A Rare Case. (2018). Global Journal of Medical Research, 18(B1), 19-21. https://medicalresearchjournal.org/index.php/GJMR/article/view/1494

Download Citation

References

Wilcock Andrew, Twycross Robert (2013) Therapeutic Reviews. 45(5), 939-949.

R Raffa, Pergolizzi Jr, J (2014) A modern analgesics pain 'pyramid. 39, 4-e6.

M Davis (2012) Twelve reasons for considering buprenorphine as frontline analgesic in the management of pain. 10, 209-219.

K Budd (1981) High dose buprenorphine for postoperative analgesia. 36, 900-903.

Joseph Pergolizzi, Anna Aloisi, Albert Dahan, Joerg Filitz, Richard Langford, Rudolf Likar, Sebastiano Mercadante, Bart Morlion, Robert Raffa, Rainer Sabatowski, Paola Sacerdote, Luis Torres, Avi Weinbroum (2010) Current Knowledge of Buprenorphine and Its Unique Pharmacological Profile. 10(5), 428-450.

Bret Berner, Vivian John (1994) Pharmacokinetic Characterisation of Transdermal Delivery Systems. 26(2), 121-134.

R Likar (2006) Transdermal buprenorphine in the management of persistent pain-safety aspects. 2(1), 115-125.

K Budd (2003) Buprenorphine and the transdermal system: the ideal match in pain management. 133, 9-e14.

Rudolf Likar, Eva-Maria Vadlau, Christian Breschan, Ingo Kager, Maria Korak-Leiter, Gerda Ziervogel (2008) Comparable Analgesic Efficacy of Transdermal Buprenorphine in Patients Over and Under 65 Years of Age. 24(6), 536-543.

Deborah Steiner, Steve Sitar, Warren Wen, Gosford Sawyerr, Catherine Munera, Steven Ripa, Craig Landau (2011) Efficacy and Safety of the Seven-Day Buprenorphine Transdermal System in Opioid-Naïve Patients with Moderate to Severe Chronic Low Back Pain: An Enriched, Randomized, Double-Blind, Placebo-Controlled Study. 42(6), 903-917.

Flemming Bach, Troels Jensen, Jens Kastrup (1991) Reply to Coe et al. 46(2), 233.

G Kress (2009) Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. 13(3), 219-230.

K Budd (2002) Evidence‐based medicine ‐ the key to sustainable practice. 24(10), 615-615.

Joseph Pergolizzi, Willem Scholten, Kevin Smith, James Leighton-Scott, Jenna Willis, Jack Henningfield (2015) The unique role of transdermal buprenorphine in the global chronic pain epidemic. 53(2), 71-76.

Sameer Desai, Santhoshi Badiger, Shreesha Tokur, Prashanth Naik (2017) Safety and efficacy of transdermal buprenorphine versus oral tramadol for the treatment of post-operative pain following surgery for fracture neck of femur: A prospective, randomised clinical study. 61(3), 225.